Insider Buying: PetVivo Holdings, Inc. (NASDAQ:PETV) CEO Buys $90,000.00 in Stock

Posted by Joseph Casey on Apr 20th, 2024

PetVivo Holdings, Inc. (NASDAQ:PETV – Get Free Report) CEO John Lai purchased 150,000 shares of the firm’s stock in a transaction dated Monday, April 15th. The stock was acquired at an average cost of $0.60 per share, for a total transaction of $90,000.00. Following the completion of the purchase, the chief executive officer now owns 1,288,592 shares of the company’s stock, valued at approximately $773,155.20. The acquisition was disclosed in a filing with the SEC, which is available at this link.

PetVivo Price Performance

NASDAQ:PETV opened at $0.74 on Friday. The company’s 50-day moving average price is $1.01 and its 200-day moving average price is $1.15. The company has a debt-to-equity ratio of 0.02, a current ratio of 0.90 and a quick ratio of 0.62. PetVivo Holdings, Inc. has a twelve month low of $0.33 and a twelve month high of $2.90.

PetVivo (NASDAQ:PETV – Get Free Report) last posted its quarterly earnings results on Monday, February 12th. The company reported ($0.12) earnings per share for the quarter. The business had revenue of $0.60 million during the quarter. PetVivo had a negative return on equity of 1,319.59% and a negative net margin of 1,016.64%.

Hedge Funds Weigh In On PetVivo

A number of institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in PetVivo by 5.2% during the first quarter. Vanguard Group Inc. now owns 226,137 shares of the company’s stock worth $461,000 after purchasing an additional 11,251 shares during the period. HighTower Advisors LLC purchased a new position in PetVivo during the first quarter worth about $40,000. Finally, Warberg Asset Management LLC purchased a new position in PetVivo during the fourth quarter worth about $29,000. 24.55% of the stock is owned by hedge funds and other institutional investors.

PetVivo Company Profile

(Get Free Report)

PetVivo Holdings, Inc, a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses.